Antiparasitic therapy in children

Troy D Moon1, Richard A Oberhelman

  • 1Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA 70112, USA. tmoon@tulane.edu

Insights

Pediatric parasitic infections pose challenges for clinicians, especially in developed nations. This article details current antiparasitic therapies for treating these increasingly common tropical diseases in children.

Area of Science:

  • Pediatric infectious diseases
  • Tropical medicine
  • Clinical pharmacology

Background:

  • Parasitic infections are globally prevalent, affecting an estimated 1 billion people with intestinal helminths alone.
  • Clinicians in developed countries often lack familiarity with managing parasitic diseases, despite increasing international travel and immigration.
  • Physicians are increasingly encountering tropical parasitic diseases due to global mobility.

Purpose of the Study:

  • To describe current approaches to antiparasitic therapy for pediatric parasitic infections.
  • To provide a comprehensive overview of antiparasitic drug treatments.
  • To aid clinicians in managing parasitic diseases in children.

Main Methods:

  • Review of current antiparasitic therapies.
  • Detailed description of drugs used for multiple parasite types.
  • Cross-referencing of drug information for clarity and efficiency.

Main Results:

  • The article presents a systematic approach to antiparasitic drug selection and usage.
  • It consolidates information on drugs effective against various parasites.
  • Emphasis is placed on practical clinical application for treating children.

Conclusions:

  • Effective management of pediatric parasitic infections requires updated clinical knowledge and accessible therapeutic guidelines.
  • Antiparasitic drug information is presented to support clinicians facing these diseases.
  • The article serves as a resource for understanding and treating a growing number of parasitic infections in children.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...